Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis
Mathew S. Maurer, Parag P. Kale, Marianna Fontana, John L. Berk, Martha A. Grogan, Finn Gustafsson, Rebecca R. Hung, Robert Gottlieb, Thibaud Damy, Alejandra González‐Duarte, Nitasha Sarswat, Yoshiki Sekijima · 2023
Read Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis by Mathew S. Maurer, Parag P. Kale, Marianna Fontana, John L. Berk, Martha A. Grogan, Finn Gustafsson, Rebecca R. Hung, Robert Gottlieb, Thibaud Damy, Alejandra González‐Duarte, Nitasha Sarswat, Yoshiki Sekijima (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/openalex-w4387966260.txt.
Description
Mathew Maurer, Parag Kale, Marianna Fontana, and colleagues tested the drug patisiran in heart disease caused by transthyretin amyloidosis. Their report appeared in the New England Journal of Medicine in 2023. In this disease, a blood protein folds wrongly and builds up in the heart, stiffening it over time. Patisiran uses RNA interference to cut production of that protein in the liver. The phase three trial was double-blind and placebo-controlled.
Three hundred sixty patients with the inherited or wild-type form of the disease took part. Half received patisiran every three weeks for twelve months, half a placebo. The main measure was change in six-minute walking distance, with quality of life scores close behind. Later measures combined deaths, heart events, and hospital visits.
Catalog record
| CREATOR | Mathew S. Maurer, Parag P. Kale, Marianna Fontana, John L. Berk, Martha A. Grogan, Finn Gustafsson, Rebecca R. Hung, Robert Gottlieb, Thibaud Damy, Alejandra González‐Duarte, Nitasha Sarswat, Yoshiki Sekijima |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 56 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | OpenAlex / New England Journal of Medicine |